Protein functionality as a potential bottleneck for somatic revertant variants - 09/01/21
Doi : 10.1016/j.jaci.2020.04.045
Fabian M.P. Kaiser, MD, MSc a, b, Ismail Reisli, MD c, Ingrid Pico-Knijnenburg, BSc d, Anton W. Langerak, PhD a, François G. Kavelaars, BSc e, Hasibe Artac, MD f, Hanna IJspeert, PhD a, ∗, Mirjam van der Burg, PhD a, d, ∗ 
a Department of Immunology, University Medical Center Rotterdam, Rotterdam, The Netherlands
b Department of Pediatrics, University Medical Center Rotterdam, Rotterdam, The Netherlands
c Department of Pediatric Immunology and Allergy, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
d Laboratory for Pediatric Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
e Department of Hematology, University Medical Center Rotterdam, Rotterdam, The Netherlands
f Department of Pediatric Immunology and Allergy, Selçuk University Medical Faculty, Konya, Turkey
| This work has been funded by the Stichting Sophia Kinderziekenhuis Fonds (grant no. S15-07 Genes and Immunity in SCID) (M.v.d.B.). |
|
| Disclosure of potential conflict of interest: The authors declare no competing financial interests. |
© 2020
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 147 - N° 1
P. 391 - janvier 2021 Retour au numéro
Article précédent
- Timing of exposure to environmental adjuvants is critical to mitigate peanut allergy
- Johanna M. Smeekens, Robert M. Immormino, Michael D. Kulis, Timothy P. Moran
- Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis
- Benjamin Ungar, Ana B. Pavel, Randall Li, Grace Kimmel, John Nia, Peter Hashim, Hee Jin Kim, Margot Chima, Anjali S. Vekaria, Yeriel Estrada, Hui Xu, Xiangyu Peng, Giselle K. Singer, Danielle Baum, Yasaman Mansouri, Mark Taliercio, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?